Resource Type

Journal Article 1

Year

2016 1

Keywords

Chinese patients 1

JAK 1

myelofibrosis 1

ruxolitinib 1

Search scope:

排序： Display mode:

Efficacy and safety of JAK inhibitor INC424 in patients with primary and post-polycythemia vera or post-essential thrombocythemia myelofibrosis in the Chinese population

Xin Du,Daobin Zhou

Frontiers of Medicine 2016, Volume 10, Issue 4,   Pages 437-443 doi: 10.1007/s11684-016-0472-9

Abstract:

A phase II study (A2202) was performed to evaluate the efficacy and safety of JAK inhibitor ruxolitinibRuxolitinib was given twice a day (bid) at a starting dose of 15 mg (n=25) or 20 mg (n=debilitating constitutional symptoms, as assessed by MFSAF v2.0, was observed in patients treated with ruxolitinibRuxolitinib treatment was generally well tolerated by Chinese patients.Ruxolitinib provided substantial reductions in splenomegaly and improvements in symptoms, and was well-tolerated

Keywords： JAK     ruxolitinib     Chinese patients     myelofibrosis    

HTML PDF Collect

Title Author Date Type Operation

Efficacy and safety of JAK inhibitor INC424 in patients with primary and post-polycythemia vera or post-essential thrombocythemia myelofibrosis in the Chinese population

Xin Du,Daobin Zhou

Journal Article